Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ivan Henriquez

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
World Journal of Clinical Oncology|February 8, 2021
Nonmetastatic castration-resistant prostate cancer: Novel agents to treat a lethal diseaseIvan Henriquez, Daniel Spratt, Alfonso Gómez-Iturriaga, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|August 11, 2025
ERG expression is not predictive of outcome in patients with intermediate- and high-risk localized prostate cancer treated with combined androgen blockade and radiotherapyIvan Henriquez, Barbara Malave, Gemma Benitez-Gabella, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|July 10, 2015
Three linked nomograms for predicting biochemical failure in prostate cancer treated with radiotherapy plus androgen deprivation therapyJose López-Torrecilla, Anna Boladeras, María Angeles Cabeza, et al.
Clinical Genitourinary Cancer|June 12, 2026
Robust Meta-Analysis of a Clinical Cell-Cycle Risk (CCR) Score Demonstrates Broadly Applicable Metastasis and Disease-Specific Mortality Risk Stratification in Men With Localized Prostate CancerTodd M Morgan, Lauren H Lenz, Ivan Henriquez, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|November 27, 2022
Management of high-risk and post-operative non-metastatic prostate cancer in Catalonia: an expert Delphi consensusMarta Bonet, David González, José-Enrique Baquedano, et al.
Journal of Neuro-Oncology|February 6, 2016
Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trialCarmen Balana, Ramon De Las Penas, Juan Manuel Sepúlveda, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|April 14, 2023
Salvage prostate brachytherapy in radiorecurrent prostate cancer: An international Delphi consensus studyMark T Corkum, Mark K Buyyounouski, Albert J Chang, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|October 29, 2025
Management of high-risk prostate cancer in Spain: results from a national patterns of care surveyVictor Duque-Santana, Maria Antonia Gómez-Aparicio, Abrahams Ocanto, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
World Journal of Clinical Oncology|February 8, 2021
Nonmetastatic castration-resistant prostate cancer: Novel agents to treat a lethal diseaseIvan Henriquez, Daniel Spratt, Alfonso Gómez-Iturriaga, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|August 11, 2025
ERG expression is not predictive of outcome in patients with intermediate- and high-risk localized prostate cancer treated with combined androgen blockade and radiotherapyIvan Henriquez, Barbara Malave, Gemma Benitez-Gabella, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|July 10, 2015
Three linked nomograms for predicting biochemical failure in prostate cancer treated with radiotherapy plus androgen deprivation therapyJose López-Torrecilla, Anna Boladeras, María Angeles Cabeza, et al.
Clinical Genitourinary Cancer|June 12, 2026
Robust Meta-Analysis of a Clinical Cell-Cycle Risk (CCR) Score Demonstrates Broadly Applicable Metastasis and Disease-Specific Mortality Risk Stratification in Men With Localized Prostate CancerTodd M Morgan, Lauren H Lenz, Ivan Henriquez, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|November 27, 2022
Management of high-risk and post-operative non-metastatic prostate cancer in Catalonia: an expert Delphi consensusMarta Bonet, David González, José-Enrique Baquedano, et al.
Journal of Neuro-Oncology|February 6, 2016
Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trialCarmen Balana, Ramon De Las Penas, Juan Manuel Sepúlveda, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|April 14, 2023
Salvage prostate brachytherapy in radiorecurrent prostate cancer: An international Delphi consensus studyMark T Corkum, Mark K Buyyounouski, Albert J Chang, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|October 29, 2025
Management of high-risk prostate cancer in Spain: results from a national patterns of care surveyVictor Duque-Santana, Maria Antonia Gómez-Aparicio, Abrahams Ocanto, et al.
Pageof 1